Table 2.

Analyses of the cumulative effect of adverse genotypes in rs4652 and rs4644 on glioblastoma risk

Glioblastoma
Genomic modelGenotypeControlCaseOR (95%CI)P
no. (%)no. (%)
rs4652
CodominantAA513 (38.3%)110 (34.0%)1.00 (reference)
CA634 (47.3%)154 (47.5%)1.14 (0.87–1.49)0.358
CC193 (14.4%)60 (18.5%)1.44 (1.01–2.06)0.044
DominantAA/CA+CC827 (61.7%)214 (66.0%)1.21 (0.94–1.56)0.148
rs4644
CodominantCC931 (68.9%)217 (67.0%)1.00 (reference)
AC396 (29.3%)91 (28.1%)1.00 (0.76–1.31)0.984
AA24 (1.8%)16 (4.9%)2.81 (1.46–5.38)0.002
RecessiveCC+AC/AA1327 (98.2%)308 (95.1%)2.81 (1.47–5.36)0.002